Drug intelligence / Profile preview

TrophiPatch

Development stage: Phase 2
Lead developer: HekeTiss
Modality: Cell Therapies
Administration: Topical

Overview

TrophiPatch is an allogeneic biological dressing composed of adipose-derived stromal cells (ASCs) for the treatment of chronic leg ulcers, such as diabetic foot ulcers and venous leg ulcers. The product utilizes stromal cells purified from donor adipose tissue, which are processed into a patch format. These cells exert therapeutic effects through the secretion of growth factors and cytokines that promote angiogenesis, modulate inflammation, and accelerate tissue regeneration. It is currently being evaluated in clinical trials for its safety and preliminary efficacy in patients with non-healing vascular or diabetic wounds.

Brand names: TrophiPatch
Other names: Adipose-derived stromal cell patch

Beyond the preview

Go deeper on TrophiPatch.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TrophiPatch.

Explore the full profile